An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody) in Patients With Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2017
At a glance
- Drugs RO 7009789 (Primary) ; Vanucizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 16 Mar 2017 Planned End Date changed from 1 Jul 2018 to 18 Jul 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 18 Jul 2018.
- 01 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.